Post Hepatitis C Cirrhosis in Sub-Sahara Kidney Transplant, Treated with Sofosbuvir/Ledipasvir: Report of Case and Review of Literature

• 作者: Ackoundou-N’Guessan Kan Clément Cherif Ibrahima Coulibaly Pessa Nawo Albert Guei Monlet Cyr Lagou Amélie Delphine Tia Weu Mélanie Tsevi Yawovi Mawufemo
• 来源期刊: 肾脏病(英文)
• 学科: 医学
• 关键词: C?te D’Ivoire Direct-Acting ANTIVIRALS KIDNEY Transplantation VIRAL Hepatitis C
• 年，卷（期）: szbyw_2017,（4）
• 页码范围: 95-100
• 页数: 6页
• 分类号: R5

摘要

Background: Viral hepatitis C is a major public health problem in the world. The advent of direct-acting antivirals has revolutionized the taking in charge and prognosis of patients infected with the hepatitis C virus. The interest of this presentation is to draw attention to the problem of therapeutic care posed by viral hepatitis C in kidney transplant patients in C?te d’Ivoire, a country with limited resources where all direct-acting antivirals are not yet available. Patient observation: We report the case of a kidney transplant of 52 years old, chronic bearer of viral hepatitis C virus who after his kidney transplant presented, decompensated active cirrhosis. A treatment based on Sofosbuvir 400 mg/Ledipasvir 90 mg in this patient with genotype 2 for 12 weeks was initiated. A sustained virological response was observed 12 weeks after the end of treatment. Conclusion: Direct-acting antivirals offer the possibility of antiviral C treatment without interferon or ribavirin in cirrhotic renal transplant.